Products for Research Use Only

Alendronic acid

CAT: 0804-HY-B0631-01Size: 25 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0631-01Size:25 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease[1].
CAS Number
66376-36-1
UNSPSC
12352211
Hazard Statement
H314, H315
Target
Bacterial
Type
Reference compound
Related Pathways
Anti-infection
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/alendronic-acid.html
Concentration
10mM
Purity
99.9
Solubility
H2O : 3.7 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
OC(P(O)(O)=O)(CCCN)P(O)(O)=O
Molecular Formula
C4H13NO7P2
Molecular Weight
249.10
Precautions
H314, H315
References & Citations
[1]Teixeira S, et al. Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma. Pharmaceutics. 2020 Mar 24;12 (3) . pii: E293.|[2]Duckworth AD, et al. Effect of Alendronic Acid on Fracture Healing: A Multicenter Randomized Placebo-Controlled Trial. J Bone Miner Res. 2019 Jun;34 (6) :1025-1032.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Cell Rep. 2022 Oct 25;41 (4) :111508.|Am J Physiol Endocrinol Metab. 2024 May 8.|Bone. 2024 Nov 29:192:117348.|Int J Mol Sci. 2024 Jul 16;25 (14) :7798.|J Biol Chem. 2019 Jul 19;294 (29) :11240-11247.|J Med Chem. 2024 Sep 12;67 (17) :15738-15755.|Pathol Res Pract. 2025 Sep:273:156138.|Biochem Pharmacol. 2025 Aug 13;242 (Pt 1) :117234.|Int J Mol Med. 2025 Dec;56 (6) :206.|J Pharm Anal. 2025 Jul 31.